Immunotherapy with chemotherapy for advanced lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of tislelizumab (an immunotherapy drug) with chemotherapy for people with a type of lung cancer that has not spread to other organs and cannot be removed with surgery. The goal is to see if this treatment can shrink tumors and help people live longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have been diagnosed with non-small cell lung cancer that is stage IIIA or IIIB and cannot be removed with surgery.
- You have not had any previous treatment for your lung cancer, such as radiation or other therapies.
- Your lung function is good enough (a breathing test will check this).
- You do not have certain gene changes in your tumor (like EGFR, ALK, ROS1, or MET).
- You are willing to provide a tumor sample for testing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of platinum-based chemotherapy, large fractionated radiotherapy, and the immunotherapy drug tislelizumab for people with stage IIIB to IV non-squamous non-small cell lung cancer. It aims to see if this approach can help control the cancer without certain gene mutations.
This trial tests combining the immunotherapy drug tislelizumab with radiation therapy for people with advanced non-squamous non-small cell lung cancer that hasn't been treated before. It aims to see if this combination helps control the cancer better than standard treatments.
This trial tests a combination of chemotherapy, radiation, and two targeted drugs (surufatinib and tislelizumab) for people with stage III non-small cell lung cancer that cannot be surgically removed. The goal is to see if this approach works better than standard treatment.
This trial combines an immunotherapy drug (tislelizumab) with chemotherapy before surgery to try to shrink the tumor and possibly make surgery possible later. The goal is to improve outcomes for people with stage III non-small cell lung cancer that is not removable at diagnosis.
This study tests whether adding a type of chemotherapy called platinum-based chemo to an immunotherapy drug called tislelizumab helps people with advanced non-small cell lung cancer that has spread and has high PD-L1. The trial aims to see if this combination works better than immunotherapy alone in people with larger tumors.
This trial tests combining the drug tislelizumab with chemotherapy for people with stage III non-small cell lung cancer that hasn't been treated yet. It aims to see if this combination can shrink or control the cancer better.
Hear when a new Unresectable Stage III Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.